RINALDI, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 1.582
EU - Europa 448
AS - Asia 159
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.250
Nazione #
US - Stati Uniti d'America 1.582
IT - Italia 89
UA - Ucraina 84
IE - Irlanda 78
SE - Svezia 75
SG - Singapore 62
CI - Costa d'Avorio 55
CN - Cina 44
DE - Germania 44
TR - Turchia 33
DK - Danimarca 23
FI - Finlandia 23
FR - Francia 14
KR - Corea 13
GB - Regno Unito 12
IN - India 7
MA - Marocco 5
BE - Belgio 3
CH - Svizzera 1
EU - Europa 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 2.250
Città #
Chandler 236
Fairfield 168
Ashburn 153
Jacksonville 134
Dublin 78
Seattle 77
Wilmington 71
Woodbridge 67
Boardman 65
Houston 64
New York 60
Des Moines 56
Abidjan 55
Cambridge 50
Ann Arbor 31
Lawrence 30
Princeton 30
San Mateo 29
Singapore 27
Turin 21
Washington 16
Los Angeles 15
San Diego 13
Helsinki 12
Norwalk 8
Beijing 6
Dallas 6
Pune 6
Shanghai 6
Falls Church 5
Saint Louis 5
Ancona 3
Castelraimondo 3
Guangzhou 3
Jiaxing 3
Kilburn 3
Montegiorgio 3
Brussels 2
Chengdu 2
Hounslow 2
London 2
Sassari 2
Wuhan 2
Acquaviva Picena 1
Bevagna 1
Chicago 1
Chiswick 1
Harrison 1
Islington 1
Liège 1
Marche 1
Milan 1
Munich 1
New Bedfont 1
New Delhi 1
Porto 1
San Benedetto Del Tronto 1
San Severino Marche 1
Taizhou 1
Wuxi 1
Xi'an 1
Totale 1.648
Nome #
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 131
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 112
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 93
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 90
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 87
Electrolyte disorders in cancer patients: a systematic review 87
Hyponatremia in cancer patients: Time for a new approach 85
Managing hyponatremia in lung cancer: latest evidence and clinical implications 85
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 83
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 83
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 82
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 81
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 79
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 76
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 74
High CTLA-4 expression correlates with poor prognosis in thymoma patients 72
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours 71
Systemic treatment for lung carcinoids: from bench to bedside 71
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies 71
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 69
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 68
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 68
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 66
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 64
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 63
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 63
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 63
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 60
Lung cancer prognosis: Can histological patterns and morphological features have a role in the management of lung cancer patients? 58
Treatment of advanced small cell lung cancer 53
Totale 2.308
Categoria #
all - tutte 12.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.710


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020140 0 0 0 0 16 0 15 1 19 17 20 52
2020/2021620 40 62 61 2 126 34 51 74 45 44 46 35
2021/2022228 17 34 16 1 4 25 7 14 19 26 26 39
2022/2023622 34 86 36 72 20 113 0 43 142 0 61 15
2023/2024371 52 7 32 14 49 110 4 41 0 15 0 47
2024/2025172 84 49 16 3 20 0 0 0 0 0 0 0
Totale 2.308